| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ticagrelor |
| Brand | Brilique® |
| Indication | Co-administered with acetylsalicylic acid (ASA), for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event. |
| Assessment Process | |
| Rapid review commissioned | 29/02/2016 |
| Rapid review completed | 04/05/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation
